Prosecution Insights
Last updated: July 17, 2026
Application No. 18/044,881

BENZO OXYGEN-CONTAINING HETEROCYCLIC COMPOUNDS AND MEDICAL APPLICATION THEREOF

Final Rejection §112
Filed
Mar 10, 2023
Priority
Sep 10, 2020 — CN 202010947909.3 +1 more
Examiner
JARRELL, NOBLE E
Art Unit
1699
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
AB Pharma Ltd.
OA Round
2 (Final)
81%
Grant Probability
Favorable
3-4
OA Rounds
0m
Est. Remaining
90%
With Interview

Examiner Intelligence

Grants 81% — above average
81%
Career Allowance Rate
837 granted / 1032 resolved
+21.1% vs TC avg
Moderate +9% lift
Without
With
+9.3%
Interview Lift
resolved cases with interview
Typical timeline
2y 11m
Avg Prosecution
67 currently pending
Career history
1087
Total Applications
across all art units

Statute-Specific Performance

§101
1.2%
-38.8% vs TC avg
§103
21.7%
-18.3% vs TC avg
§102
18.8%
-21.2% vs TC avg
§112
33.4%
-6.6% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1032 resolved cases

Office Action

§112
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Response to Amendment The 2026 May 6 amendment containing claims 24-29 is acknowledged. The objections and rejections of 2026 February 25 are overcome for the following reasons: the phrase “mixtures thereof” is not recited in the new claims; claims 1-23 are now cancelled; and SHI (WO 2011159327, published 2011 December 22) does not recite compounds in which examined variables E and G1 form an -O-C(RcRd)- group with each other. Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Newly added claims 24-29 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. The dashed bond connecting variables L1 and R2 has unclear metes and bounds. Is it meant to describe that these two variables can forma ring with one another? In the claim set of 2023 March 10, the following text is present: PNG media_image1.png 68 572 media_image1.png Greyscale Is this the interpretation that applicants intend? The new claims do not contain this language. A broad range or limitation together with a narrow range or limitation that falls within the broad range or limitation (in the same claim) may be considered indefinite if the resulting claim does not clearly set forth the metes and bounds of the patent protection desired. See MPEP § 2173.05(c). In the present instance, claims 24-29 recites the broad recitation of a compound of formula IIb, and the claim also recites compounds IIb-18, IIb-25, IIb-43, and IIb-46, which is the narrower statement of the range/limitation. The claim(s) are considered indefinite because there is a question or doubt as to whether the feature introduced by such narrower language is (a) merely exemplary of the remainder of the claim, and therefore not required, or (b) a required feature of the claims. Due to the scope of formula IIb being broader than each of the specific compounds, a broad and narrow groups are present in the same claim. In the specific compounds, variable R7 is OH. In the broad group R7 is eleven different groups including hydroxyl. Regarding claim 24, the phrase "such as" renders the claim indefinite because it is unclear whether the limitations following the phrase are part of the claimed invention. The language “(NRiRj)” is interpreted as such language because the language “(NRiRj)” is one embodiment of an alkylamino group for variable X5. See MPEP § 2173.05(d). Conclusion Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Claims 24-29 are not allowed. The following is a statement of reasons for the indication of allowable subject matter: SHI (WO 2011159327, published 2011 December 22, cited in previous action) describes example 262 (page 271, lines 9-15). This compound does not anticipate of render obvious a compound of formula IIb because variable E and G1 are not permitted to form an -O=CH=CH- group with each other. PNG media_image2.png 206 676 media_image2.png Greyscale Any inquiry concerning this communication or earlier communications from the examiner should be directed to NOBLE E JARRELL whose telephone number is (571)272-9077. The examiner can normally be reached 9:00 AM to 5:00 PM. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Fereydoun Sajjadi can be reached at 571-272-3311. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /NOBLE E JARRELL/Primary Examiner, Art Unit 1699
Read full office action

Prosecution Timeline

Mar 10, 2023
Application Filed
Feb 25, 2026
Non-Final Rejection mailed — §112
May 06, 2026
Response Filed
Jun 24, 2026
Final Rejection mailed — §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12679841
PYRIMIDOPYRIMIDINONES USEFUL AS WEE-1 KINASE INHIBITORS
4y 7m to grant Granted Jul 14, 2026
Patent 12679858
METAL IRIDIUM COMPLEX AND USE THEREOF
3y 7m to grant Granted Jul 14, 2026
Patent 12679818
RADIOACTIVE HALOGEN LABELING PRECURSOR COMPOUND
3y 2m to grant Granted Jul 14, 2026
Patent 12679825
CRYSTALLINE AND AMORPHOUS FORMS OF A DELTA-OPIOID MODULATOR
3y 2m to grant Granted Jul 14, 2026
Patent 12668593
PYRAZOLE COMPOUND AND PREPARATION METHOD THEREFOR AND USE THEREOF
3y 5m to grant Granted Jun 30, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
81%
Grant Probability
90%
With Interview (+9.3%)
2y 11m (~0m remaining)
Median Time to Grant
Moderate
PTA Risk
Based on 1032 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month